/ERNA
ERNA Stock - Ernexa Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$1.31+3.97%
+$0.05 (+3.97%) • Dec 19
37
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.8
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.44
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ERNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.30 – $1.32
TARGET (TP)$1.51
STOP LOSS$1.21
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta6.72
52W High$14.40
52W Low$1.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $582,000 | $68,000 | N/A | N/A | N/A |
| Gross Profit | $486,000 | $-168,000 | N/A | N/A | $-98,000 |
| Gross Margin | 83.5% | -247.1% | N/A | N/A | N/A |
| Operating Income | $-15,674,000 | $-21,135,000 | $-33,217,000 | $-113,732,000 | $-7,248,000 |
| Net Income | $-44,539,000 | $-21,668,000 | $-24,579,000 | $-122,545,000 | $11.91M |
| Net Margin | -7652.7% | -31864.7% | N/A | N/A | N/A |
| EPS | $-1.57 | $-4.08 | $-8.06 | $-56.61 | $-3.51 |
Company Overview
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ERNABeat Rate
25%
Last 4 quarters
Avg Surprise
-4.6%
EPS vs Estimate
Beats / Misses
1/3
Last 12 quarters
Latest EPS
$-0.15
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | — | $-0.15 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.61 | — | — |
Q2 2025 | May 7, 2025 | — | $-2.25 | — | — |
Q1 2025 | Mar 12, 2025 | — | $-1.14 | — | — |
Q4 2024 | Nov 12, 2024 | — | $-4.92 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-1.02 | — | — |
Q2 2024 | May 14, 2024 | — | $-1.23 | — | — |
Q1 2024 | Mar 14, 2024 | — | $-1.14 | — | — |
Q4 2023 | Nov 13, 2023 | — | $-1.03 | — | — |
Q3 2023 | Aug 11, 2023 | — | $-0.85 | — | — |
Q2 2023 | May 11, 2023 | — | $-1.06 | — | — |
Q1 2023 | Mar 20, 2023 | — | $-1.24 | — | — |
Q4 2022 | Nov 14, 2022 | $-2.20 | $-2.49 | -13.2% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-2.60 | $-1.20 | +53.8% | ✓ BEAT |
Q3 2022 | Jul 1, 2022 | $-2.80 | $-3.40 | -21.4% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-3.25 | — | — |
Q4 2021 | Nov 9, 2021 | $-1.60 | $-2.20 | -37.5% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | — | $-4.75 | — | — |
Latest News
Ernexa Therapeutics Presents New Preclinical Data On Its Lead Cell Therapy Candidate, ERNA-101, At ASH Annual Meeting
📈 PositiveBenzinga•Dec 8, 2025, 01:34 PM
Reported November 7, 2025: Ernexa Therapeutics Q3 EPS $(0.15) Up From $(73.70) YoY
📈 PositiveBenzinga•Nov 10, 2025, 01:51 PM
Ernexa Therapeutics shares are trading higher after the company announced it entered into a collaboration with Cellipont Bioservices to focus on engineering, differentiation and production to advance ERNA-101 toward clinical trials in ovarian cancer.
📈 PositiveBenzinga•Oct 29, 2025, 01:12 PM
Ernexa Therapeutics And Cellipont Bioservices Enter Cell Therapy Manufacturing Partnership To Focus On Engineering, Differentiation And Production To Advance ERNA-101 Toward Clinical Trials In Ovarian Cancer
📈 PositiveBenzinga•Oct 29, 2025, 12:36 PM
Ernexa Therapeutics To Present Preclinical Data On Gene-Modified iPS-Derived MSCs Reprogramming Immune Microenvironment In High-Grade Serous Ovarian Cancer At AACR Conference On September 20
📈 PositiveBenzinga•Sep 17, 2025, 12:36 PM
CORRECTION: Ernexa Therapeutics Cuts Operating Loss Decreased By $5.5M, Or 51%, From $10.7M During The 6-Months Ending On June 30, 2024 To $5.2M During The 6-Months Ending On June 30, 2025
📈 PositiveBenzinga•Sep 10, 2025, 12:49 PM
Ernexa Therapeutics stock plummets on announcing 1-for-15 reverse stock split
📉 NegativeSeeking Alpha•Jun 10, 2025, 01:34 PM
Frequently Asked Questions about ERNA
What is ERNA's current stock price?
Ernexa Therapeutics Inc. (ERNA) is currently trading at $1.31 per share. The stock has moved +3.97% today.
What is the analyst price target for ERNA?
No analyst price targets are currently available for this stock.
What sector is Ernexa Therapeutics Inc. in?
Ernexa Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ERNA's market cap?
Ernexa Therapeutics Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does ERNA pay dividends?
No, Ernexa Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
AEMD
Aethlon Medical, Inc.
$2.86
Mkt Cap: $0.0B
AEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$6.45
Mkt Cap: $0.0B
LNAI
Lunai Bioworks Inc.
$1.05
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
MPLT
MapLight Therapeutics, Inc.
$20.55
Mkt Cap: $0.0B
OSRH
OSR Holdings, Inc.
$0.65
Mkt Cap: $0.0B
PHGE
BiomX Inc.
$2.13
Mkt Cap: $0.0B
PMN
ProMIS Neurosciences, Inc.
$8.55
Mkt Cap: $0.0B
Explore stocks similar to ERNA for comparison